Corporate News
Directorate Change
13 August 2024
Cambridge Nutritional Sciences plc (AIM:CNSL), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, announces that James Cooper, currently Chief Operating Officer, has been appointed as interim Chief Executive Officer of CNSL with immediate effect. After two years as CEO, and thirteen years with the Company, Jag Grewal has tendered his resignation and stepped down from the Board with immediate effect.
Jag will continue to work with the Board to effect an orderly handover.
In his brief tenure as COO, James has demonstrated a wide range of operational and management skills and the Board is confident he will be a very capable interim CEO.
Cally Rand, Chair of CNSL , said:
"Jag has been an integral part of the business over the last thirteen years and has managed the business extremely well as CNSL has transitioned away from infectious disease diagnostics. I would also like to extend my sincere thanks to Jag for the huge role he has played in the foundation and development of this Company. On behalf of the entire Board, we wish him the best for the future"
Jag Grewal commented:
"I have deeply enjoyed leading CNS plc and working alongside such a dedicated and talented team and supportive Board. I want to express my deepest gratitude to the Board, our leadership team, and all of our employees for their support, collaboration and hard work during my tenure. I am confident that the Company is in a strong position to continue its trajectory of growth and success."
Contacts:
Cambridge Nutritional Sciences PLC | |
Cally Rand Executive Chair | |
Cavendish Capital Markets Limited | Tel: 020 7220 0500 |
Geoff Nash / Edward Whiley / (Corporate Finance) | |
Nigel Birks / Harriet Ward (ECM) |
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (MAR) as in force in the United Kingdom pursuant to the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via Regulatory Information Service (RIS), this inside information is now considered to be in the public domain.